KR20240163120A - 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 - Google Patents

Info

Publication number

KR20240163120A

KR20240163120A KR1020247034222A KR20247034222A KR20240163120A KR 20240163120 A KR20240163120 A KR 20240163120A KR 1020247034222 A KR1020247034222 A KR 1020247034222A KR 20247034222 A KR20247034222 A KR 20247034222A KR 20240163120 A KR20240163120 A KR 20240163120A

Authority

KR

South Korea

Prior art keywords

alkyl

compound

heterocyclyl

aryl

pharmaceutically acceptable

Prior art date

2022-03-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract description 5
• 229910052725 zinc Inorganic materials 0.000 title abstract description 5
• 239000011701 zinc Substances 0.000 title abstract description 5
• 108010013958 Ikaros Transcription Factor Proteins 0.000 title description 6
• 102000017182 Ikaros Transcription Factor Human genes 0.000 title description 6
• 150000001875 compounds Chemical class 0.000 claims abstract description 615
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 73
• 201000010099 disease Diseases 0.000 claims abstract description 68
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
• 239000003814 drug Substances 0.000 claims abstract description 43
• 201000011510 cancer Diseases 0.000 claims abstract description 31
• 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims abstract description 27
• 102100037796 Zinc finger protein Helios Human genes 0.000 claims abstract description 27
• 238000004519 manufacturing process Methods 0.000 claims abstract description 9
• 125000000623 heterocyclic group Chemical group 0.000 claims description 485
• 125000003118 aryl group Chemical group 0.000 claims description 447
• 150000003839 salts Chemical class 0.000 claims description 407
• 125000001072 heteroaryl group Chemical group 0.000 claims description 396
• 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 344
• 125000000217 alkyl group Chemical group 0.000 claims description 283
• 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims description 211
• 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 206
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 155
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 151
• -1 -OH Chemical group 0.000 claims description 150
• 229910052736 halogen Inorganic materials 0.000 claims description 124
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 115
• 150000002367 halogens Chemical class 0.000 claims description 115
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 98
• 125000005842 heteroatom Chemical group 0.000 claims description 96
• 125000003545 alkoxy group Chemical group 0.000 claims description 95
• 229910052739 hydrogen Inorganic materials 0.000 claims description 93
• 229910052760 oxygen Inorganic materials 0.000 claims description 92
• 229910052799 carbon Inorganic materials 0.000 claims description 88
• 229910052717 sulfur Inorganic materials 0.000 claims description 87
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 85
• 229910052757 nitrogen Inorganic materials 0.000 claims description 67
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 64
• 229910052805 deuterium Inorganic materials 0.000 claims description 64
• 125000001188 haloalkyl group Chemical group 0.000 claims description 60
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 44
• 238000000034 method Methods 0.000 claims description 44
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 40
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 40
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 39
• 239000001301 oxygen Substances 0.000 claims description 38
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 37
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 37
• 239000011593 sulfur Substances 0.000 claims description 37
• 125000003342 alkenyl group Chemical group 0.000 claims description 36
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 36
• 239000008194 pharmaceutical composition Substances 0.000 claims description 36
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 36
• 229940124597 therapeutic agent Drugs 0.000 claims description 35
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 34
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 34
• 125000000304 alkynyl group Chemical group 0.000 claims description 33
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 30
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 29
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 24
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 22
• 239000003795 chemical substances by application Substances 0.000 claims description 21
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 20
• 238000011282 treatment Methods 0.000 claims description 20
• 125000005843 halogen group Chemical group 0.000 claims description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
• 125000003566 oxetanyl group Chemical group 0.000 claims description 18
• 125000004043 oxo group Chemical group O=* 0.000 claims description 14
• 239000001257 hydrogen Substances 0.000 claims description 12
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
• 125000005936 piperidyl group Chemical group 0.000 claims description 10
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
• LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 claims description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• 125000001841 imino group Chemical group [H]N=* 0.000 claims description 8
• 125000003551 oxepanyl group Chemical group 0.000 claims description 8
• 125000004076 pyridyl group Chemical group 0.000 claims description 8
• LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 claims description 8
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 7
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 7
• 150000002431 hydrogen Chemical class 0.000 claims description 7
• 239000003112 inhibitor Substances 0.000 claims description 7
• 235000012054 meals Nutrition 0.000 claims description 7
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 7
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 6
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 125000001624 naphthyl group Chemical group 0.000 claims description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 206010042971 T-cell lymphoma Diseases 0.000 claims description 5
• 239000000611 antibody drug conjugate Substances 0.000 claims description 5
• 229940049595 antibody-drug conjugate Drugs 0.000 claims description 5
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
• 125000000335 thiazolyl group Chemical group 0.000 claims description 5
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 4
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 4
• 125000000532 dioxanyl group Chemical group 0.000 claims description 4
• 201000003444 follicular lymphoma Diseases 0.000 claims description 4
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
• 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 230000002489 hematologic effect Effects 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 238000001959 radiotherapy Methods 0.000 claims description 2
• 125000001425 triazolyl group Chemical group 0.000 claims description 2
• 238000011277 treatment modality Methods 0.000 claims 4
• BUXIAWLTBSXYSW-UHFFFAOYSA-N 3-[2-amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile Chemical group CC1=C(C=CC=C1C1=CC(=NC(N)=N1)C1=CN(CC2=NC(=CC=C2)C(C)(C)O)N=N1)C#N BUXIAWLTBSXYSW-UHFFFAOYSA-N 0.000 claims 3
• MFYLCAMJNGIULC-KCVUFLITSA-N [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid Chemical group C[C@H](NC1=CC(Cl)=NC2=C1C=NN2[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O)C1=CC=CC=C1F MFYLCAMJNGIULC-KCVUFLITSA-N 0.000 claims 3
• 229940127272 CD73 inhibitor Drugs 0.000 claims 2
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 2
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 2
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
• 229940123309 Immune checkpoint modulator Drugs 0.000 claims 2
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
• 229940121359 adenosine receptor antagonist Drugs 0.000 claims 2
• 108700025316 aldesleukin Proteins 0.000 claims 2
• 229950002916 avelumab Drugs 0.000 claims 2
• 229940121413 bempegaldesleukin Drugs 0.000 claims 2
• 229940121581 magrolimab Drugs 0.000 claims 2
• 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 2
• 229950000143 sacituzumab govitecan Drugs 0.000 claims 2
• ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 claims 2
• 229940052007 zimberelimab Drugs 0.000 claims 2
• JODKFOVZURLVTG-UHFFFAOYSA-N 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Chemical compound [O-][N+](=O)C1([N+]([O-])=O)CN(C(=O)CBr)C1 JODKFOVZURLVTG-UHFFFAOYSA-N 0.000 claims 1
• 229940125559 AB154 Drugs 0.000 claims 1
• 229940127277 BI-765063 Drugs 0.000 claims 1
• 229940125557 BMS-986207 Drugs 0.000 claims 1
• 206010005003 Bladder cancer Diseases 0.000 claims 1
• 238000011357 CAR T-cell therapy Methods 0.000 claims 1
• 229940121900 Flt-3 agonist Drugs 0.000 claims 1
• 229940126656 GS-4224 Drugs 0.000 claims 1
• 229940125962 HPK1 kinase inhibitor Drugs 0.000 claims 1
• 108010002350 Interleukin-2 Proteins 0.000 claims 1
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
• 108700031757 NKTR-214 Proteins 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
• 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
• 206010057644 Testis cancer Diseases 0.000 claims 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
• 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
• 229960005310 aldesleukin Drugs 0.000 claims 1
• 230000002424 anti-apoptotic effect Effects 0.000 claims 1
• 229960003852 atezolizumab Drugs 0.000 claims 1
• 229950009579 axicabtagene ciloleucel Drugs 0.000 claims 1
• 229940121530 balstilimab Drugs 0.000 claims 1
• 229940125163 brexucabtagene autoleucel Drugs 0.000 claims 1
• 229940121418 budigalimab Drugs 0.000 claims 1
• 229950007712 camrelizumab Drugs 0.000 claims 1
• 229940121420 cemiplimab Drugs 0.000 claims 1
• 229940067219 cetrelimab Drugs 0.000 claims 1
• 239000012829 chemotherapy agent Substances 0.000 claims 1
• 229940011248 cosibelimab Drugs 0.000 claims 1
• 229940054557 datopotamab deruxtecan Drugs 0.000 claims 1
• 229940121432 dostarlimab Drugs 0.000 claims 1
• 229950009791 durvalumab Drugs 0.000 claims 1
• 229950004930 enfortumab vedotin Drugs 0.000 claims 1
• 229940121556 envafolimab Drugs 0.000 claims 1
• 229940115924 etigilimab Drugs 0.000 claims 1
• 229940125033 etrumadenant Drugs 0.000 claims 1
• 206010017758 gastric cancer Diseases 0.000 claims 1
• 229960003445 idelalisib Drugs 0.000 claims 1
• YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical group C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
• 229960005386 ipilimumab Drugs 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 229940125052 lemzoparlimab Drugs 0.000 claims 1
• 229940067578 letaplimab Drugs 0.000 claims 1
• 229940014803 lodapolimab Drugs 0.000 claims 1
• 229940125264 mupadolimab Drugs 0.000 claims 1
• 229940067657 nemvaleukin alfa Drugs 0.000 claims 1
• 229960003301 nivolumab Drugs 0.000 claims 1
• 229940059392 oleclumab Drugs 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 229950010773 pidilizumab Drugs 0.000 claims 1
• 229940087463 proleukin Drugs 0.000 claims 1
• 229940121482 prolgolimab Drugs 0.000 claims 1
• 229940125094 quemliclustat Drugs 0.000 claims 1
• 229940018007 retifanlimab Drugs 0.000 claims 1
• 229940018073 sasanlimab Drugs 0.000 claims 1
• 229940121497 sintilimab Drugs 0.000 claims 1
• 229950007213 spartalizumab Drugs 0.000 claims 1
• 201000011549 stomach cancer Diseases 0.000 claims 1
• 238000001356 surgical procedure Methods 0.000 claims 1
• ATFXVNUWQOXRRU-UHFFFAOYSA-N taminadenant Chemical compound BrC=1C(N)=NC(N2N=CC=C2)=NC=1N1C=CC=N1 ATFXVNUWQOXRRU-UHFFFAOYSA-N 0.000 claims 1
• 229940121619 taminadenant Drugs 0.000 claims 1
• 201000003120 testicular cancer Diseases 0.000 claims 1
• 229950007133 tiragolumab Drugs 0.000 claims 1
• 229950007123 tislelizumab Drugs 0.000 claims 1
• 229940121514 toripalimab Drugs 0.000 claims 1
• 229940049679 trastuzumab deruxtecan Drugs 0.000 claims 1
• 229950007217 tremelimumab Drugs 0.000 claims 1
• 229940125118 uliledlimab Drugs 0.000 claims 1
• 201000005112 urinary bladder cancer Diseases 0.000 claims 1
• 206010046766 uterine cancer Diseases 0.000 claims 1
• 229940020434 vibostolimab Drugs 0.000 claims 1
• 229940121638 zalifrelimab Drugs 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 103
• 102000004169 proteins and genes Human genes 0.000 abstract description 69
• 230000000593 degrading effect Effects 0.000 abstract description 12
• 239000001064 degrader Substances 0.000 abstract description 11
• 101000599046 Homo sapiens Zinc finger protein Eos Proteins 0.000 abstract description 8
• 102100037793 Zinc finger protein Eos Human genes 0.000 abstract description 8
• 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 abstract description 5
• 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 abstract description 5
• 235000018102 proteins Nutrition 0.000 description 67
• 239000000203 mixture Substances 0.000 description 46
• 125000004432 carbon atom Chemical group C* 0.000 description 29
• 210000004027 cell Anatomy 0.000 description 27
• 125000001424 substituent group Chemical group 0.000 description 23
• 230000015556 catabolic process Effects 0.000 description 19
• 238000006731 degradation reaction Methods 0.000 description 19
• 201000009030 Carcinoma Diseases 0.000 description 17
• 125000004429 atom Chemical group 0.000 description 14
• 125000004122 cyclic group Chemical group 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 206010041823 squamous cell carcinoma Diseases 0.000 description 11
• 241000282414 Homo sapiens Species 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
• 125000003107 substituted aryl group Chemical group 0.000 description 10
• 206010003571 Astrocytoma Diseases 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 239000003937 drug carrier Substances 0.000 description 9
• 229940002612 prodrug Drugs 0.000 description 9
• 239000000651 prodrug Substances 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 8
• 208000009956 adenocarcinoma Diseases 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 208000006265 Renal cell carcinoma Diseases 0.000 description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 6
• 206010014967 Ependymoma Diseases 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 6
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
• 201000010133 Oligodendroglioma Diseases 0.000 description 6
• 230000001668 ameliorated effect Effects 0.000 description 6
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 6
• 239000012453 solvate Substances 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 201000000274 Carcinosarcoma Diseases 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 125000003636 chemical group Chemical group 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 125000003367 polycyclic group Chemical group 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 210000003289 regulatory T cell Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
• 208000003200 Adenoma Diseases 0.000 description 4
• 206010001233 Adenoma benign Diseases 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 206010024627 liposarcoma Diseases 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 150000007522 mineralic acids Chemical class 0.000 description 4
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 4
• 201000011519 neuroendocrine tumor Diseases 0.000 description 4
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
• 150000007524 organic acids Chemical class 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 125000003003 spiro group Chemical group 0.000 description 4
• 238000013456 study Methods 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
• 102100022464 5'-nucleotidase Human genes 0.000 description 3
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
• 102100036664 Adenosine deaminase Human genes 0.000 description 3
• 102100022749 Aminopeptidase N Human genes 0.000 description 3
• 201000003076 Angiosarcoma Diseases 0.000 description 3
• 201000005262 Chondroma Diseases 0.000 description 3
• 208000005243 Chondrosarcoma Diseases 0.000 description 3
• 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 3
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 208000001258 Hemangiosarcoma Diseases 0.000 description 3
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
• 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 3
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 3
• 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 3
• 101001002579 Homo sapiens Zinc finger protein Pegasus Proteins 0.000 description 3
• 102000037978 Immune checkpoint receptors Human genes 0.000 description 3
• 108091008028 Immune checkpoint receptors Proteins 0.000 description 3
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
• 208000018142 Leiomyosarcoma Diseases 0.000 description 3
• 208000007054 Medullary Carcinoma Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 3
• 102100020893 Zinc finger protein Pegasus Human genes 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 3
• 125000005466 alkylenyl group Chemical group 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 229940125844 compound 46 Drugs 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 235000019000 fluorine Nutrition 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
• 125000004404 heteroalkyl group Chemical group 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000004073 interleukin-2 production Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 230000000955 neuroendocrine Effects 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000012743 protein tagging Effects 0.000 description 3
• 230000017854 proteolysis Effects 0.000 description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 206010042863 synovial sarcoma Diseases 0.000 description 3
• 238000003419 tautomerization reaction Methods 0.000 description 3
• 206010044412 transitional cell carcinoma Diseases 0.000 description 3
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 2
• 102100036962 5'-3' exoribonuclease 1 Human genes 0.000 description 2
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
• 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 2
• 102100033715 Apolipoprotein A-I Human genes 0.000 description 2
• 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 description 2
• 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
• 108010049990 CD13 Antigens Proteins 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
• 201000009047 Chordoma Diseases 0.000 description 2
• 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• 208000008334 Dermatofibrosarcoma Diseases 0.000 description 2
• 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 2
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000835276 Homo sapiens 3-ketoacyl-CoA thiolase, mitochondrial Proteins 0.000 description 2
• 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 2
• 101000890622 Homo sapiens Apoptosis-inducing factor 1, mitochondrial Proteins 0.000 description 2
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
• 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 2
• 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 208000006937 Hydatidiform mole Diseases 0.000 description 2
• 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
• 206010023256 Juvenile melanoma benign Diseases 0.000 description 2
• 206010023347 Keratoacanthoma Diseases 0.000 description 2
• 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
• 241001596784 Pegasus Species 0.000 description 2
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
• 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
• 206010045515 Undifferentiated sarcoma Diseases 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 108091007916 Zinc finger transcription factors Proteins 0.000 description 2
• 102000038627 Zinc finger transcription factors Human genes 0.000 description 2
• 208000006336 acinar cell carcinoma Diseases 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 208000010029 ameloblastoma Diseases 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 208000028435 angiomyxoma Diseases 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 208000002458 carcinoid tumor Diseases 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
• 201000000292 clear cell sarcoma Diseases 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 208000012106 cystic neoplasm Diseases 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 201000006827 desmoid tumor Diseases 0.000 description 2
• 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 230000036267 drug metabolism Effects 0.000 description 2
• 208000016139 endolymphatic sac tumor Diseases 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 201000000330 endometrial stromal sarcoma Diseases 0.000 description 2
• 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 2
• 201000001169 fibrillary astrocytoma Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 201000008361 ganglioneuroma Diseases 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 230000000155 isotopic effect Effects 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 208000025278 malignant myoepithelioma Diseases 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 201000003020 metanephric adenoma Diseases 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 201000003731 mucosal melanoma Diseases 0.000 description 2
• 208000009091 myxoma Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 201000008026 nephroblastoma Diseases 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 208000028591 pheochromocytoma Diseases 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 238000002600 positron emission tomography Methods 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 208000014212 sarcomatoid carcinoma Diseases 0.000 description 2
• 230000008684 selective degradation Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 208000005893 serous cystadenoma Diseases 0.000 description 2
• 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 2
• 238000002603 single-photon emission computed tomography Methods 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 210000004872 soft tissue Anatomy 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 238000000954 titration curve Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
• 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
• 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• DPGQSDLGKGLNHC-UHFFFAOYSA-N 1,1-diethylcyclopentane Chemical compound CCC1(CC)CCCC1 DPGQSDLGKGLNHC-UHFFFAOYSA-N 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 1
• SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 1
• DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• FZMQHKLFUMGAAO-UHFFFAOYSA-N 4-benzyl-4-methylpiperidine Chemical compound C=1C=CC=CC=1CC1(C)CCNCC1 FZMQHKLFUMGAAO-UHFFFAOYSA-N 0.000 description 1
• 108050004870 5'-3' exoribonuclease 1 Proteins 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
• 230000035502 ADME Effects 0.000 description 1
• 108060000255 AIM2 Proteins 0.000 description 1
• 102000000872 ATM Human genes 0.000 description 1
• 102100021222 ATP-dependent Clp protease proteolytic subunit, mitochondrial Human genes 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
• 208000005641 Adenomyosis Diseases 0.000 description 1
• 102100033346 Adenosine receptor A1 Human genes 0.000 description 1
• 102100035984 Adenosine receptor A2b Human genes 0.000 description 1
• 102100036006 Adenosine receptor A3 Human genes 0.000 description 1
• 102000009346 Adenosine receptors Human genes 0.000 description 1
• 108050000203 Adenosine receptors Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
• 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
• 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 208000008884 Aneurysmal Bone Cysts Diseases 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 102100034594 Angiopoietin-1 Human genes 0.000 description 1
• 102100034608 Angiopoietin-2 Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
• 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
• 102000004881 Angiotensinogen Human genes 0.000 description 1
• 108090001067 Angiotensinogen Proteins 0.000 description 1
• 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
• 101710143255 Apoptosis-inducing factor 1 Proteins 0.000 description 1
• 101000638670 Arabidopsis thaliana 3-ketoacyl-CoA thiolase 2, peroxisomal Proteins 0.000 description 1
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
• 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
• 108091007065 BIRCs Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000023514 Barrett esophagus Diseases 0.000 description 1
• 208000023665 Barrett oesophagus Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004453 Benign salivary gland neoplasm Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010061005 Cardiac myxoma Diseases 0.000 description 1
• 102100028914 Catenin beta-1 Human genes 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000010126 Chondromatosis Diseases 0.000 description 1
• 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 208000013440 Complete hydatidiform mole Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 201000005171 Cystadenoma Diseases 0.000 description 1
• 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
• 101150046567 DAO gene Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 241000289632 Dasypodidae Species 0.000 description 1
• 206010059352 Desmoid tumour Diseases 0.000 description 1
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 208000029497 Elastoma Diseases 0.000 description 1
• 208000034715 Enchondroma Diseases 0.000 description 1
• 208000027666 Endometrial Stromal Tumors Diseases 0.000 description 1
• 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
• 108090000860 Endopeptidase Clp Proteins 0.000 description 1
• 241000854350 Enicospilus group Species 0.000 description 1
• 206010014968 Ependymoma malignant Diseases 0.000 description 1
• 208000005163 Extra-Adrenal Paraganglioma Diseases 0.000 description 1
• 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 description 1
• 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 208000008961 Fibrous Dysplasia of Bone Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 201000004066 Ganglioglioma Diseases 0.000 description 1
• 206010055008 Gastric sarcoma Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000021309 Germ cell tumor Diseases 0.000 description 1
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
• 206010018404 Glucagonoma Diseases 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101001004358 Homo sapiens 1-alkyl-2-acetylglycerophosphocholine esterase Proteins 0.000 description 1
• 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
• 101000804879 Homo sapiens 5'-3' exoribonuclease 1 Proteins 0.000 description 1
• 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
• 101100491236 Homo sapiens AOC1 gene Proteins 0.000 description 1
• 101000750222 Homo sapiens ATP-dependent Clp protease proteolytic subunit, mitochondrial Proteins 0.000 description 1
• 101000799712 Homo sapiens Adenosine receptor A1 Proteins 0.000 description 1
• 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 description 1
• 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
• 101000889548 Homo sapiens Amiloride-sensitive amine oxidase [copper-containing] Proteins 0.000 description 1
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
• 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
• 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
• 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 1
• 101100452383 Homo sapiens IKZF2 gene Proteins 0.000 description 1
• 101000599868 Homo sapiens Intercellular adhesion molecule 4 Proteins 0.000 description 1
• 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
• 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
• 101000923332 Homo sapiens Protein asteroid homolog 1 Proteins 0.000 description 1
• 101000889523 Homo sapiens Retina-specific copper amine oxidase Proteins 0.000 description 1
• 101100364841 Homo sapiens SALL4 gene Proteins 0.000 description 1
• 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 1
• 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 101000625338 Homo sapiens Transcriptional adapter 1 Proteins 0.000 description 1
• 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 101150086468 IKZF2 gene Proteins 0.000 description 1
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
• 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
• 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 1
• 206010071677 Intravenous leiomyomatosis Diseases 0.000 description 1
• 208000005125 Invasive Hydatidiform Mole Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
• 208000004138 Lymphangiomyoma Diseases 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 201000001853 McCune-Albright syndrome Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 108091092878 Microsatellite Proteins 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
• 208000009287 Myoepithelioma Diseases 0.000 description 1
• 235000009421 Myristica fragrans Nutrition 0.000 description 1
• 206010066948 Myxofibrosarcoma Diseases 0.000 description 1
• 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
• 241000232901 Nephroma Species 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 108010027206 Nucleopolyhedrovirus inhibitor of apoptosis Proteins 0.000 description 1
• 208000012247 Oligodendroglial tumor Diseases 0.000 description 1
• 206010048757 Oncocytoma Diseases 0.000 description 1
• 208000004179 Oral Leukoplakia Diseases 0.000 description 1
• 208000001715 Osteoblastoma Diseases 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
• 208000013438 Partial hydatidiform mole Diseases 0.000 description 1
• 108010079855 Peptide Aptamers Proteins 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 201000007288 Pleomorphic xanthoastrocytoma Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
• 108091008611 Protein Kinase B Proteins 0.000 description 1
• 102100032661 Protein asteroid homolog 1 Human genes 0.000 description 1
• 201000008183 Pulmonary blastoma Diseases 0.000 description 1
• 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
• 102100039141 Retina-specific copper amine oxidase Human genes 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• 206010073334 Rhabdoid tumour Diseases 0.000 description 1
• 101150041225 SALL4 gene Proteins 0.000 description 1
• 102100020824 Serine-protein kinase ATM Human genes 0.000 description 1
• 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 1
• 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
• 206010041329 Somatostatinoma Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 235000019892 Stellar Nutrition 0.000 description 1
• 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
• 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 241001061127 Thione Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000037280 Trisomy Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102100026803 Type-1 angiotensin II receptor Human genes 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• 208000021146 Warthin tumor Diseases 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 206010059394 acanthoma Diseases 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 201000002942 acinar cell cystadenocarcinoma Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 208000002938 adenomyoma Diseases 0.000 description 1
• 201000001256 adenosarcoma Diseases 0.000 description 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 210000001943 adrenal medulla Anatomy 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 108091008108 affimer Proteins 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 208000014534 anaplastic ependymoma Diseases 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940127131 antibody-peptide-conjugate Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 201000002097 bile duct cystadenocarcinoma Diseases 0.000 description 1
• 208000010687 biliary cystadenocarcinoma Diseases 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
• 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 201000011143 bone giant cell tumor Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 201000007452 breast secretory carcinoma Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 201000002748 carcinoma of supraglottis Diseases 0.000 description 1
• 210000001011 carotid body Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• 239000007958 cherry flavor Substances 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 201000005217 chondroblastoma Diseases 0.000 description 1
• 201000001902 chondroid lipoma Diseases 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 201000010276 collecting duct carcinoma Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 208000030381 cutaneous melanoma Diseases 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
• MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 101150077852 dao1 gene Proteins 0.000 description 1
• 125000005891 decahydronaphthyridinyl group Chemical group 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 208000030347 dedifferentiated chondrosarcoma Diseases 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 238000000375 direct analysis in real time Methods 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000012063 dual-affinity re-targeting Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 208000014616 embryonal neoplasm Diseases 0.000 description 1
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 201000006828 endometrial hyperplasia Diseases 0.000 description 1
• 208000016018 endometrial polyp Diseases 0.000 description 1
• 201000004388 endometrial stromal nodule Diseases 0.000 description 1
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
• 201000009274 endometriosis of uterus Diseases 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002085 enols Chemical group 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
• 201000010103 fibrous dysplasia Diseases 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
• 201000011587 gastric lymphoma Diseases 0.000 description 1
• 208000017211 gastric neuroendocrine tumor G1 Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
• 201000011610 giant cell glioblastoma Diseases 0.000 description 1
• 201000010215 giant hemangioma Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 208000002409 gliosarcoma Diseases 0.000 description 1
• 201000004958 glottis carcinoma Diseases 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000017759 head and neck paraganglioma Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 229940126533 immune checkpoint blocker Drugs 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000005445 isotope effect Effects 0.000 description 1
• 201000005263 juxtacortical chondroma Diseases 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 208000024596 kidney oncocytoma Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 208000028533 laryngeal sarcoma Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 201000011015 lipid-rich carcinoma Diseases 0.000 description 1
• 208000010033 lipoblastoma Diseases 0.000 description 1
• 201000005252 lipomatous cancer Diseases 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
• 239000001115 mace Substances 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 201000008405 myoepithelial carcinoma Diseases 0.000 description 1
• 208000026226 myoepithelial tumor Diseases 0.000 description 1
• 201000004057 myxopapillary ependymoma Diseases 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000025351 nephroma Diseases 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 201000011682 nervous system cancer Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000016359 neuroblastic tumor Diseases 0.000 description 1
• 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 208000013937 oligoastrocytic tumor Diseases 0.000 description 1
• 244000309459 oncolytic virus Species 0.000 description 1
• 208000008511 optic nerve glioma Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000024948 pancreatic acinar cell cystadenocarcinoma Diseases 0.000 description 1
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 208000002820 pancreatoblastoma Diseases 0.000 description 1
• 201000010148 papillary adenoma Diseases 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 208000024975 periosteal chondroma Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 201000008814 placenta cancer Diseases 0.000 description 1
• 208000024361 placenta neoplasm Diseases 0.000 description 1
• 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
• 201000010968 pleomorphic carcinoma Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 201000002267 posterior uveal melanoma Diseases 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
• 229940125415 protein degrader Drugs 0.000 description 1
• 230000007026 protein scission Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 208000005039 renal oncocytoma Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 201000007321 sebaceous carcinoma Diseases 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 208000019694 serous adenocarcinoma Diseases 0.000 description 1
• 208000016596 serous neoplasm Diseases 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 201000003708 skin melanoma Diseases 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 208000014653 solitary fibrous tumor Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 1
• 201000002757 subglottis carcinoma Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000005306 thianaphthenyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 206010046811 uterine polyp Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 208000022752 well-differentiated liposarcoma Diseases 0.000 description 1